Document:

WAIVER TO

MEMORANDUM OF UNDERSTANDING

AND ASSET ASSIGNMENT AGREEMENT

 

Whereas,
, Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”), Imagic, LLC (“Imagic”),
and Richard L. Chang Holding's, LLC (“Holdings LLC”) entered into a Memorandum of Understanding and Asset
Assignment Agreement dated as of July 16, 2013 (the “Agreement”).

 

Whereas,
the Agreement granted a right of reversion to Imagic for the Patent Assets (as defined in the Agreement) in the event a certain
amount of financing did not occur, and the amounts of such financing have not occurred as of the date hereof;

 

Whereas,
the Company desires Imagic and Holdings LLC to waive and terminate the right of reversion in order to provide certainty to the
Company and its shareholders for its future operations;

 

Now,
Therefore, for good and valuable consideration, including, without limitation, receipt of payment in the amount of $20,000,
the receipt and sufficiency of which is acknowledged, the parties agree as follows:

 

1.                  
Right of Reversion Terminated. Imagic and Holdings LLC hereby forever waive and
terminate the right of reversion to the Patent Assets granted to them under the Agreement.

 

2.                  
Agreement. All other terms and conditions of the Agreement shall remain in full
force and effect.

 

In
Witness Whereof, the undersigned have caused their authorized representatives to execute this Agreement as of January
17, 2014. 

 

	IMAGIC, LLC	RICHARD L. CHANG’S HOLDINGS, LLC
	
        /s/ Ben Chang

        By: Ben Chang
	
        /s/ Richard Chang

        By Richard L. Chang, Sole Member and Manager

 

Acknowledged and Agreed:

 

Rich Pharmaceuticals, Inc.

 

By: /s/ Ben Chang

Ben Chang, CEOAGREEMENT OF CONVEYANCE, TRANSFER
AND ASSIGNMENT OF ASSETS AND ASSUMPTION OF OBLIGATIONS

This Agreement of
Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (“Transfer and Assumption Agreement”)
is made as of January 16, 2014, by Remmington Enterprises, Inc., a Nevada corporation (“Assignor”), and Gary
A. Scoggins (“Assignee”).

 

WHEREAS, Assignor has been
engaged in the business of owning and exploring certain mining claims in Mineral County, Nevada (the “Business”);
and

 

WHEREAS, Assignor desires
to convey, transfer and assign to Assignee, and Assignee desires to acquire from Assignor, all of the assets of Assignor relating
to the operation of the Business, and in connection therewith, Assignee has agreed to assume all of the liabilities of Assignor
relating to the Business, on the terms and conditions set forth herein.

 

NOW THEREFORE, in
consideration of the mutual promises and agreements contained herein, the parties hereto, intending to be legally bound hereby,
agree as follows:

 

Section 1.Assignment.

 

1.1.Assignment
of Assets. For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged by Assignor,
Assignor does hereby assign, grant, bargain, sell, convey, transfer and deliver to Assignee, and its successors and assigns, all
of Assignor’s right, title and interest in, to and under the assets, properties and business, of every kind and description,
wherever located, real, personal or mixed, tangible or intangible, owned, held or used in the conduct of the Business, including,
but not limited to, certain unpatented mining claims located in Mineral County, Nevada designated as BLM Nos. NMC 1035534 through
NMC 1035537, and commonly known as Remington #1 through Remington #4 (the “Assets”).

 

1.2Further Assurances.
Assignor shall from time to time after the date hereof at the request of Assignee and without further consideration execute and
deliver to Assignee such additional instruments of transfer and assignment, including without limitation any bills of sale, assignments
of leases, deeds, and other recordable instruments of assignment, transfer and conveyance, in addition to this Transfer and Assumption
Agreement, as Assignee shall reasonably request to evidence more fully the assignment by Assignor to Assignee of the Assets.

 

Section 2. Assumption.

 

2.1Assumed Liabilities.
As of the date hereof, Assignee hereby assumes and agrees to pay, perform and discharge, fully and completely, (i) all
liabilities, commitments, contracts, agreements, obligations or other claims against Assignor, whether known or unknown,
asserted or unasserted, accrued or unaccrued, absolute or contingent, liquidated or unliquidated, due or to become due, and whether
contractual, statutory, or otherwise associated with the Business (the “Liabilities”).

 

2.2Further Assurances.
Assignee shall from time to time after the date hereof at the request of Assignor and without further consideration execute and
deliver to Assignor such additional instruments of assumption in addition to this Transfer and Assumption Agreement as Assignor
shall reasonably request to evidence more fully the assumption by Assignee of the Liabilities.

 

Section 3.Headings.
The descriptive headings contained in this Transfer and Assumption Agreement
are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Transfer and Assumption
Agreement.

 

Section 4.Governing
Law. This Transfer and Assumption Agreement shall
be governed by and construed in accordance with the laws of the State of Nevada applicable to contracts made and to be performed
entirely within that state, except that any conveyances of leaseholds and real property made herein shall be governed by the laws
of the respective jurisdictions in which such property is located.

 

[The remainder of this page is blank
intentionally.]

    	 

    	 

    

IN WITNESS WHEREOF,
this Transfer and Assumption Agreement has been duly executed and delivered by the parties hereto as of the date first above written.

 

REMMINGTON ENTERPRISES,
INC.

 

 

 

By: /s/ Gary A. Scoggins

 Gary A. Scoggins

 President

 

 

 

/s/ Gary A. Scoggins

GARY A. SCOGGINS

    	2Exhibit 10.7.5

 

FOURTH AMENDMENT

TO

LICENSE AGREEMENT

between The University of South Carolina
Research Foundation 

and NephroGenex, Inc. (assignee of BioStratum
Incorporated) 

 

This Fourth Amendment to the License Agreement
(“Fourth Amendment”) is made effective as of the date of the last signature to this Amendment (“Fourth Amendment
Effective Date”) by and between the South Carolina Research Foundation (“SCRF”) and NephroGenex, Inc., a Delaware
corporation (“LICENSEE”) and assignee of BioStratum Incorporated (“BioStratum”).

 

SCRF and LICENSEE (collectively, “the
Parties”) entered into a License Agreement, dated August 27, 2004 (the “Agreement”). The Parties wish to amend
the Agreement in accordance with Article 15-11 of such Agreement, and agree that the Agreement is hereby amended as set forth below.
Capitalized terms used in this Fourth Amendment that are not otherwise defined herein, shall have the respective meanings set forth
in the Agreement.

 

Amendment. Certain
terms of the Agreement are amended and replaced as follows:

 

Amended Article 4.1B

 

Annual License Fees shall be due in the amounts
listed below, with the first such annual License Fee be due and payable on January 1, 2006 and each succeeding Annual License Fee
being due and payable on the according to the following schedule:

 

	2006-2008	$30,000 due on January 1 of each year
	2009-2010	$60,000 due on January 1 of each year
	2011	Total of $62,000 with $20,000 due June 30, 2011 and $42,000 due December 31, 2011
	2012	Total of $62,000 with $10,000 due April 15, 2012; $52,000 due August 30, 2013.
	2013	Total of $122,000 with $20,000 due August 30, 2013, $20,000 due December 31, 2013 and $82,000 due March 31, 2014
	2014 and thereafter	Total of $120,000 yearly with $30,000 due quarterly on March 31;  June 30; September 30, and December 31 of each year

 

Annual License Fees shall be due and payable
as long as LICENSEE is actively marketing or has an active sublicense for Pyridorin. Annual License Fees paid each year shall be
creditable only against Licensed Product Sublicense upfront fees and milestone payments (defined in Article 4-1.C. and 4-1.E. respectively)
earned and payable in the same calendar year.

 

Scope of Amendment. This Fourth Amendment
supersedes all proposals, oral, or written, all negotiations, conversations, or discussions between or among parties relating to
the subject matter of this Fourth Amendment and all past dealings or industry customs. This Fourth Amendment shall be integrated
in and form part of the Agreement upon execution. All terms

 

    	1

    	 

    

 

and conditions of the Agreement shall remain
unchanged except as modified by this Fourth Agreement and the terms of the Agreement, as modified by this Fourth Amendment, are
hereby ratified and confirmed. Where the terms of the Agreement conflict with those of this Fourth Amendment, however, the terms
of this Fourth Amendment shall control. This Fourth Amendment may be executed by electronic copy or facsimile and in two (2) or
more counterparts, each of which shall be deemed an original and all of which together shall constitute but one and the same instrument.

 

Termination of this Amendment. If this
Amendment is not signed within fifteen (15) business days after receipt, then the amendment and its terms shall become null and
void. Also, if the total payment of one hundred twelve thousand dollars ($112,000) is not received by March 31, 2014, then the
Amendment and its terms shall become null and void.

 

NOTICES, PAYMENT, AND OTHER COMMUNICATIONS

 

Any payment, notice or other communication
required or permitted to be made or given to either Party hereto pursuant to this Agreement shall be sufficiently made or given
on the date of mailing if sent to such Party by certified United States Postal Service Express Mail, or by utilizing an express
courier service (such as Federal Express, DHL, etc.), addressed to it at the address set forth below, or to such other address
as the recipient shall have designated by written notice given to the other Party as follows:

 

In the Case of SCRF:

 

South Carolina Research Foundation

Technology Commercialization Office

Horizon I, 541 Main Street Columbia,
South Carolina 29201 

Attn: Tiffany Beverly

 

In the Case of NephroGenex:

 

Bob Peterson

Vice President of Product Development
& Regulatory Affairs

NephroGenex, Inc.

4401 Research Commons Building, Suite
290

79 T.W. Alexander Drive

P.O. Box 14188

Research Triangle Park, NC 27709-4188

Office: (609) 986-1788

Cell: (609) 216-3045

peterson@nephrogenex.com

 

Payments may be made by wire transfer rather
than by certified mail. If payment is made by wire transfer, written notice that payment was made by wire transfer must be made
in accordance with the provisions of the above paragraph. Wire transfers should be made to the following account:

 

Name on Account:

Account Number:

Routing Number:

 

    	2

    	 

    

 

IN WITNESS WHEREOF this Amendment has been
executed as of the Amendment Effective Date by the parties hereto by their respective duly authorized representatives.

 

	UNIVERSITY OF SOUTH CAROLINA	 	NEPHROGENEX, INC.
	RESEARCH FOUNDATION	 	 	 
	 	 	 	 	 
	By: 	/s/ Chad Hardaway	 	 	By: 	/s/ Pierre Legault	 
	 	 	 	 	 
	Name: 	Chad Hardaway	 	 	Name: 	Pierre Legault	 
	Title: 	Director, Technology Commercialization	 	Title: 	Chief Executive Officer	 
	 	 	 	 	 
	Date: 	1/14/14	 	 	Date: 	January 10, 2014	 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]